Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24047-24060

  Woo, Jong Kyu ^a   Kang, Ju Hee ^b   Kim, BoRa ^b   Park, Byung Hee ^a   Shin, Kum Joo ^c   Song, Seong Won ^d   Kim, Jung Ju ^d   Kim, Hwan Mook ^a   Lee, Sang Jin ^b   Oh, Seung Hyun ^a  

^a Gachon University   (South Korea)

^b National Cancer Center   (South Korea)

^c Bio Age Inc   (South Korea)

^d Yooyoung Pharmaceutical Co   (South Korea)

Author keywords

Chemoresistance; Colorectal cancer; Hepatocyte growth factor (HGF); Irinotecan (CPT 11); Microenvironment

Indexed keywords

CYTOKINE ANTIBODY; HUMANIZED HEPATOCYTE GROWTH FACTOR ANTIBODY; IRINOTECAN; MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; CAMPTOTHECIN; CONDITIONED MEDIUM; HGF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG SENSITIVITY; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PROTEIN TARGETING; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CONDITIONED MEDIUM; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; HCT 116 CELL LINE; HT-29 CELL LINE; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PHARMACOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CULTURE MEDIA, CONDITIONED; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FIBROBLASTS; HCT116 CELLS; HEPATOCYTE GROWTH FACTOR; HT29 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84943427644     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4369     Document Type: Article

References (57)

1. Yoshida S, Harada T, Iwabe T, Taniguchi F, Fujii A, Sakamoto Y, Yamauchi N, Shiota G and Terakawa N. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. The Journal of clinical endocrinology and metabolism. 2002;87:2376-2383.
2. Felix AS, Edwards RP, Stone RA, Chivukula M, Parwani AV, Bowser R, Linkov F and Weissfeld JL. Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. British journal of cancer. 2012;106:2004-2009.
3. Felix AS, Stone RA, Chivukula M, Bowser R, Parwani AV, Linkov F, Edwards RP and Weissfeld JL. Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression. International journal of cancer Journal international du cancer. 2012; 131:E114-121.
4. Nakamura T, Teramoto H, Tomita Y and Ichihara A. L-proline is an essential amino acid for hepatocyte growth in culture. Biochemical and biophysical research communications. 1984;122:884-891.
5. Luetteke NC and Michalopoulos GK. Partial purification and characterization of a hepatocyte growth factor produced by rat hepatocellular carcinoma cells. Cancer research. 1985;45:6331-6337.
6. Funakoshi H and Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clinica chimica acta;international journal of clinical chemistry. 2003; 327:1-23.
7. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R and Fan TP. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arteriosclerosis, thrombosis, and vascular biology. 2003;23:69-75.
8. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT and Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. The American journal of pathology. 1995;147:386-396.
9. Stella MC, Trusolino L and Comoglio PM. The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Molecular biology of the cell. 2009;20:642-657.
10. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF. Met, metastasis, motility and more. Nature reviews Molecular cell biology. 2003;4:915-925.
11. Bissell MJ, Radisky DC, Rizki A, Weaver VM and Petersen OW. The organizing principle:microenvironmental influences in the normal and malignant breast. Differentiation;research in biological diversity. 2002; 70:537-546.
12. Tripathi M, Billet S and Bhowmick NA. Understanding the role of stromal fibroblasts in cancer progression. Cell adhesion & migration. 2012;6:231-235.
13. Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, et al. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clinical cancer research :an official journal of the American Association for Cancer Research. 2014;20:5796-5807.
14. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D and Couderc B. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer letters. 2012;326:59-68.
15. Tlsty TD and Coussens LM. Tumor stroma and regulation of cancer development. Annual review of pathology. 2006; 1:119-150.
16. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, Scherer PE, Capozza F and Lisanti MP. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment:a new genetically tractable model for human cancer associated fibroblasts. Cancer biology & therapy. 2011;11:383-394.
17. Erez N, Truitt M, Olson P, Arron ST and Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer cell. 2010; 17:135-147.
18. De Boeck A, Hendrix A, Maynard D, Van Bockstal M, Daniels A, Pauwels P, Gespach C, Bracke M and De Wever O. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics. 2013;13:379-388.
19. Mao Y, Keller ET, Garfield DH, Shen K and Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer metastasis reviews. 2013;32:303-315.
20. Sugimoto H, Mundel TM, Kieran MW and Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer biology & therapy. 2006; 5:1640-1646.
21. Bhowmick NA, Neilson EG and Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.
22. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K and Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. The American journal of pathology. 2011;179:1483-1493.
23. Yan XL, Fu CJ, Chen L, Qin JH, Zeng Q, Yuan HF, Nan X, Chen HX, Zhou JN, Lin YL, Zhang XM, Yu CZ, Yue W and Pei XT. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast cancer research and treatment. 2012; 132:153-164.
24. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M and Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS one. 2009;4:e4992.
25. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kwong DL and Guan XY. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/beta-catenin signalling pathway. Gut. 2011;60:1635-1643.
26. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC and Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer research. 2001;61:5911-5918.
27. Turner N and Grose R. Fibroblast growth factor signalling: from development to cancer. Nature reviews Cancer. 2010; 10:116-129.
28. Olson OC and Joyce JA. Microenvironment-mediated resistance to anticancer therapies. Cell research. 2013; 23:179-181.
29. Engelman JA and Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current opinion in genetics & development. 2008;18:73-79.
30. Natan S, Tsarfaty G, Horev J, Haklai R, Kloog Y and Tsarfaty I. Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy. Oncoscience. 2014;1:30-38.
31. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-509.
32. Hack SP, Bruey JM and Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer:a review of clinical and biomarker development. Oncotarget. 2014;5:2866-2880.
33. Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S and Ferlini C. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 2014;5:4855-4867.
34. Joyce JA and Pollard JW. Microenvironmental regulation of metastasis. Nature reviews Cancer. 2009;9:239-252.
35. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC and Mitsiades CS. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature medicine. 2010;16:483-489.
36. Shekhar MP, Santner S, Carolin KA and Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. The American journal of pathology. 2007;170:1546-1560.
37. Sonnenberg E, Meyer D, Weidner KM and Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. The Journal of cell biology. 1993;123:223-235.
38. Matsumoto K and Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. International journal of cancer Journal international du cancer. 2006;119:477-483.
39. Xu Y and Villalona-Calero MA. Irinotecan:mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of oncology :official journal of the European Society for Medical Oncology/ESMO. 2002; 13:1841-1851.
40. Pommier Y. Topoisomerase I inhibitors:camptothecins and beyond. Nature reviews Cancer. 2006;6:789-802.
41. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. Journal of clinical oncology :official journal of the American Society of Clinical Oncology. 1993;11:909-913.
42. Ikeguchi M, Arai Y, Maeta Y, Ashida K, Katano K and Wakatsuki T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surgery today. 2011;41:1196-1199.
43. Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V and Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer:a pilot phase II trial. British journal of cancer. 2012;107:1932-1937.
44. Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cleau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M and Borg C. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab:clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC cancer. 2013;13:611.
45. Dayan D, Salo T, Salo S, Nyberg P, Nurmenniemi S, Costea DE and Vered M. Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer. Cancer medicine. 2012;1:128-140.
46. Castells M, Thibault B, Delord JP and Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. International journal of molecular sciences. 2012; 13:9545-9571.
47. Blagosklonny MV. Rapalogs in cancer prevention:antiaging or anticancer? Cancer biology & therapy. 2012; 13:1349-1354.
48. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV and Lisanti MP. Caveolin-1 and accelerated host aging in the breast tumor microenvironment:chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. The American journal of pathology. 2012;181:278-293.
49. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y and Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells:in vitro analysis of tumor-stromal interactions. Cancer research. 1997;57:3305-3313.
50. Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P and Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Laboratory investigation;a journal of technical methods and pathology. 2010;90:1346-1356.
51. Liu Y, Liu JH, Chai K, Tashiro S, Onodera S and Ikejima T. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonininduced A549 lung cancer cells. The Journal of pharmacy and pharmacology. 2013;65:1622-1642.
52. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M and Takeyama H. Interleukin-6 released by colon cancerassociated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. British journal of cancer. 2014;110:469-478.
53. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K and Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast cancer research :BCR. 2012;14:R104.
54. Han W, Wang W, Mohammed KA and Su Y. Alphadefensins increase lung fibroblast proliferation and collagen synthesis via the beta-catenin signaling pathway. The FEBS journal. 2009;276:6603-6614.
55. Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS and Kim CW. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene. 2012;31:2187-2198.
56. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T and Sessa WC. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circulation research. 2002;90:866-873.
57. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK and Lee HY. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. Journal of the National Cancer Institute. 2007;99:949-961.